Compare Neurocrine Biosciences Inc (NBIX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Wells Fargo & Co — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Wells Fargo & Co trades at $90 (market cap $265.99B). The key difference: Wells Fargo & Co is far larger — about 16.9× Neurocrine Biosciences Inc's market cap, and Wells Fargo & Co pays a 2.27% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WFC | |
|---|---|---|
Market Cap | $15.77B | $265.99B |
Sector | Health | Financials |
52-Week High | $185.50 | $96.40 |
52-Week Low | $123.10 | $73.42 |
Enterprise Value | $15.78B | — |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Wells Fargo (WFC) trades at $87.98, down 2.21% on the day, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 12.78, net income margin of 25.97%, and recent Q2 2026 earnings beat. CEO Charlie Scharf emphasized strategic initiatives at the 2026 healthcare conference (CNBC, 2026-09-09), while the bank expands its wealth management division (Bloomberg via Yahoo Finance, 2026-08-28).
Outlook is cautiously positive with a consensus price target of $97.64, though risks include volatile cash flows and regulatory scrutiny. Investment opportunity lies in sustained profitability improvements and ROTCE targets, but investors face headwinds from interest rate sensitivity and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
